Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Commissions a Rs 75 cr viral antigen unit, inaugurates new filling plant

Hyderabad-based vaccine maker Indian Immunologicals (IIL) on Wednesday started work on a Rs 75 crore viral antigen manufacturing facility in Genome Valley, Telangana that will enhance its viral vaccine making capacity by 35 per cent by October 2021.

The company has a pipeline of viral vaccines including Zika, dengue, varicella, as well as a potential Covid-19 inoculation. The new viral antigen facility will be specially designed as a multi-product facility.

IIL also inaugurated a sterile filling facility today that has come up with an investment of Rs 75 crore.

K Anand Kumar, Managing Director of IIL said “We are optimistic